“I am honored to have been one of the members the Prix Galien Italy jury. It is an Italian excellence, and an example of an evaluation process based on scientific rigor. However, given my new institutional commitment, I feel that I can no longer be part of the board, even if I have been able to appreciate the absolute independence of the assessment of the most innovative drugs.”

– Dr. Stefano Vella, currently President of the Italian Medicines Agency (AIFA) and Director of the Center for Global Health of the Italian Institute of Health (ISS), was a board member of the Prix Galien Italy jury until April 2017

Visit PrixGalienItaly

Contact: Alessandro Gallo



  • Chemical synthesis drug: Kisqali® (ribociclib), Novartis
  • Biological drug: Hemlibra (emicizumab), Roche
  • Orphan drug: Onpattro® (patisiran), Alnylam Pharmaceuticals
  • Advanced therapy: Luxturna® (voretigene neparvovec), Novartis
  • Real World Evidence: Zostavax® (Herpes Zoster vaccine), MSD

For acomprehensivelist ofpast winnersvisit ourHall of Fame

The Prix Galien Award is the biomedical industry's highest accolade, recognizing the development of the world’s most innovative medicines and devices.